HYPMY
Price
$5.09
Change
+$0.24 (+4.95%)
Updated
Nov 18 closing price
Capitalization
3.06B
Intraday BUY SELL Signals
INIS
Price
$0.06
Change
-$0.01 (-14.29%)
Updated
Nov 18 closing price
Capitalization
29.2M
Intraday BUY SELL Signals
Interact to see
Advertisement

HYPMY vs INIS

Header iconHYPMY vs INIS Comparison
Open Charts HYPMY vs INISBanner chart's image
Hypera SA
Price$5.09
Change+$0.24 (+4.95%)
Volume$1.75K
Capitalization3.06B
International Isotopes
Price$0.06
Change-$0.01 (-14.29%)
Volume$93.99K
Capitalization29.2M
HYPMY vs INIS Comparison Chart in %
HYPMY
Daily Signal:
Gain/Loss:
INIS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
HYPMY vs. INIS commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HYPMY is a Hold and INIS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (HYPMY: $5.09 vs. INIS: $0.06)
Brand notoriety: HYPMY and INIS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HYPMY: 16% vs. INIS: 68%
Market capitalization -- HYPMY: $3.05B vs. INIS: $33.31M
HYPMY [@Pharmaceuticals: Generic] is valued at $3.05B. INIS’s [@Pharmaceuticals: Generic] market capitalization is $33.31M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HYPMY’s FA Score shows that 2 FA rating(s) are green whileINIS’s FA Score has 1 green FA rating(s).

  • HYPMY’s FA Score: 2 green, 3 red.
  • INIS’s FA Score: 1 green, 4 red.
According to our system of comparison, HYPMY is a better buy in the long-term than INIS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HYPMY’s TA Score shows that 6 TA indicator(s) are bullish while INIS’s TA Score has 4 bullish TA indicator(s).

  • HYPMY’s TA Score: 6 bullish, 4 bearish.
  • INIS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, HYPMY is a better buy in the short-term than INIS.

Price Growth

HYPMY (@Pharmaceuticals: Generic) experienced а +3.25% price change this week, while INIS (@Pharmaceuticals: Generic) price change was -38.56% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.77%. For the same industry, the average monthly price growth was -6.55%, and the average quarterly price growth was +28.28%.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.77% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HYPMY($3.06B) has a higher market cap than INIS($29.2M). HYPMY YTD gains are higher at: 75.588 vs. INIS (60.756). HYPMY has higher annual earnings (EBITDA): 1.61B vs. INIS (855K). HYPMY has more cash in the bank: 1.86B vs. INIS (1.86M). INIS has less debt than HYPMY: INIS (4.82M) vs HYPMY (9.16B). HYPMY has higher revenues than INIS: HYPMY (6.97B) vs INIS (14.7M).
HYPMYINISHYPMY / INIS
Capitalization3.06B29.2M10,466%
EBITDA1.61B855K188,772%
Gain YTD75.58860.756124%
P/E Ratio20.84N/A-
Revenue6.97B14.7M47,435%
Total Cash1.86B1.86M100,269%
Total Debt9.16B4.82M189,861%
FUNDAMENTALS RATINGS
HYPMY vs INIS: Fundamental Ratings
HYPMY
INIS
OUTLOOK RATING
1..100
2483
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
80
Overvalued
PROFIT vs RISK RATING
1..100
9097
SMR RATING
1..100
7685
PRICE GROWTH RATING
1..100
3940
P/E GROWTH RATING
1..100
55
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HYPMY's Valuation (10) in the null industry is significantly better than the same rating for INIS (80). This means that HYPMY’s stock grew significantly faster than INIS’s over the last 12 months.

HYPMY's Profit vs Risk Rating (90) in the null industry is in the same range as INIS (97). This means that HYPMY’s stock grew similarly to INIS’s over the last 12 months.

HYPMY's SMR Rating (76) in the null industry is in the same range as INIS (85). This means that HYPMY’s stock grew similarly to INIS’s over the last 12 months.

HYPMY's Price Growth Rating (39) in the null industry is in the same range as INIS (40). This means that HYPMY’s stock grew similarly to INIS’s over the last 12 months.

HYPMY's P/E Growth Rating (5) in the null industry is in the same range as INIS (5). This means that HYPMY’s stock grew similarly to INIS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HYPMYINIS
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 17 days ago
72%
Declines
ODDS (%)
Bearish Trend 14 days ago
71%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
HYPMY
Daily Signal:
Gain/Loss:
INIS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HKUOY15.17N/A
N/A
Hakuhodo Dy Holdings, Inc.
KTYCF9.65N/A
N/A
Kits Eyecare Ltd.
BLIDF43.97N/A
N/A
Boliden AB
EMMS1.90N/A
N/A
Emmis Corporation
JNCCD0.07N/A
N/A
Metalite Resources Inc.

HYPMY and

Correlation & Price change

A.I.dvisor tells us that HYPMY and PLNH have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HYPMY and PLNH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HYPMY
1D Price
Change %
HYPMY100%
+4.95%
PLNH - HYPMY
21%
Poorly correlated
-3.54%
CPIX - HYPMY
20%
Poorly correlated
+3.68%
GLASF - HYPMY
20%
Poorly correlated
-3.74%
KMDA - HYPMY
20%
Poorly correlated
-0.39%
JUSHF - HYPMY
18%
Poorly correlated
-2.63%
More

INIS and

Correlation & Price change

A.I.dvisor tells us that INIS and HLTRF have been poorly correlated (+17% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INIS and HLTRF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INIS
1D Price
Change %
INIS100%
-15.57%
HLTRF - INIS
17%
Poorly correlated
N/A
GRUSF - INIS
10%
Poorly correlated
+1.22%
HSTI - INIS
9%
Poorly correlated
N/A
HYPMY - INIS
3%
Poorly correlated
+4.95%
IPSEF - INIS
2%
Poorly correlated
N/A
More